6-month Progression-Free Survival (PFS6) as a prognostic factor in large B-cell lymphoma patients undergoing chimeric antigen receptor T-cell therapy: A real-world multicenter study
Annals of Hematology · 14.03.2026 · 105 (4)
DOI: 10.1007/s00277-026-06910-8 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Annals of Hematology, online erschienen am 14.03.2026. Verfasst von Zhangyan Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Center, School of Medicine, Sichuan Cancer Hospital and I…. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Lymphoma, Large B-Cell, Diffuse, Receptors, Chimeric Antigen. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the National Natural Science Foundation of China, Cancer Innovative Research Program of Sun Yat-sen University Cancer Center.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Center, School of Medicine, Sichuan Cancer Hospital and Institute, University of Electronic Science and Technology of China, Ch…
- Department of Gynecologic Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Center, Sichuan Cancer Hospital & Institute, University of Electronic Science and Technology of China, Chengdu, Sichuan, Ch…
- Department of Oncology, The Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, China.
- Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China. linty@sysucc.org.cn.
Förderung
- the National Natural Science Foundation of China
- Cancer Innovative Research Program of Sun Yat-sen University Cancer Center
Zitieren
APA
Wang, Z., Liu, X., Hong, H., & Lin, T. (2026). 6-month Progression-Free Survival (PFS6) as a prognostic factor in large B-cell lymphoma patients undergoing chimeric antigen receptor T-cell therapy: A real-world multicenter study. Annals of Hematology, 105(4). https://doi.org/10.1007/s00277-026-06910-8
Vancouver
Wang Z, Liu X, Hong H, Lin T. 6-month Progression-Free Survival (PFS6) as a prognostic factor in large B-cell lymphoma patients undergoing chimeric antigen receptor T-cell therapy: A real-world multicenter study. Annals of Hematology. 2026;105(4). doi:10.1007/s00277-026-06910-8
BibTeX
@article{Wang2026,
author = {Wang, Zhangyan and Liu, Xiaoshi and Hong, Huangming and Lin, Tongyu},
title = {6-month Progression-Free Survival (PFS6) as a prognostic factor in large B-cell lymphoma patients undergoing chimeric antigen receptor T-cell therapy: A real-world multicenter study},
journal = {Annals of Hematology},
year = {2026},
volume = {105},
number = {4},
doi = {10.1007/s00277-026-06910-8}
}
EUVIMED